Schering-Plough Launches Rebetrol for Hepatitis C in Germany

August 1999
Worldwide Biotech;Aug99, Vol. 11 Issue 8, p1
Trade Publication
Reports that Schering-Plough Corp. has launched in Germany its Rebetrol for the treatment of both relapsed and untreated hepatitis C patients. Background on the drug; Drugs being marketed by Schering-Plough in the United States; Comments from Milan Panic, chairman and chief executive officer of ICN Pharmaceuticals.


Related Articles

  • FDA committee forwards Intron for review. Shaw, Kendall // Drug Store News;5/25/98, Vol. 20 Issue 8, pCP22 

    Reports that Schering-Plough's Intron A (interferon alfa-2b, recombinant for injection) and Rebetol (ribavirin, USP) capsules combination therapy is safe and effective for treating chronic hepatitis C patients with liver disease who have relapsed following alpha interferon therapy in the United...

  • Rebetron studies support new indication.  // Drug Store News;12/14/98, Vol. 20 Issue 20, pCP24 

    Cites a study showing that Schering-Plough's hepatitis C treatment, Rebetron, can be considerably more effective against chronic hepatitis C than monotherapy in patients who have never been treated for the disease.

  • FDA committee forwards Intron for review. Shaw, Kendall // Discount Store News;5/25/98, Vol. 37 Issue 10, pCP22 

    Reports that the Antiviral Drugs Advisory Committee has forwarded for review to the US Food & Drug Administration, Schering-Plough Corp.'s Intron A antiviral agent and Rebetol combination therapy indicated for the treatment of chronic hepatitis C in patients 18 years old and above.

  • Try, try again.  // Drug Topics;8/21/95, Vol. 139 Issue 16, p19 

    Reports on Schering-Plough's plan to license ICN's ribavirin to develop a new combination therapy for hepatitis C.

  • FDA ASSIGNS PRIORITY REVIEW STATUS TO PEG-INTRON/REBETOL.  // Biotech Business;May2001, Vol. 14 Issue 5, p3 

    Reports on the decision of the United States Food and Drug Administration to assign priority review status to Schering-Plough's supplemental Biologics License Application to market PEG-INTRON (peginterferon alfa-2b) Powder for Injection for use in combination therapy with Rebetol capsules for...

  • Claritin in rapid-dissolve formulation.  // Drug Topics;1/20/97, Vol. 141 Issue 2, p8 

    Reports on Schering-Plough Corp.'s receipt of Food and Drug Administration clearance for Claritin RediTabs, a non-drowsy allergy product in ready-to-take form.

  • Schering-Plough: shorter hepatitis C therapies offer limited advantage.  // PharmaWatch: Monthly Review;August 2004, Vol. 3 Issue 8, p30 

    Within the highly competitive hepatitis C market, pharmaceutical companies Schering-Plough Corp. and Roche Inc. have gone head to head in recent years with similar flagship products. While the recommendation of a shorter Peglntron/Rebetol combination therapy course looks positive for...

  • HEPATITIS C DRUG CUTS MELANOMA.  // Dermatology Times;Aug2008, Vol. 29 Issue 8, p24 

    The article focuses on the medical study published in the journal "Lancet," which shows the effect of hepatitis C drugs on melanoma in London, England. It states that pegintron, a hepatitis C drug, from Schering-Plough Corp. helps stop the return of melanoma after surgery. According to a...

  • Front-line defense.  // Pharmaceutical Executive;Feb98, Vol. 18 Issue 2, p104 

    Reports on Schering-Plough's announcement of the availability of Fareston (toremifene) as a first-line treatment for metastatic breast cancer in postmenopausal women with estrogen receptor positive or unknown tumors. Mechanism of action of the drug; Dosage.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics